Global Pharmaceutical Technology :: A Best B2B solution, Best Media Portal for Pharmaceutical Industry.

In our Q210 Pharmaceutical Business Environment Ratings (BER) matrix for Asia Pacific, Cambodia’s immature pharmaceutical market is found in last position of the 16 markets surveyed within the region. One of the most recent additions to our pharmaceutical and healthcare universe, which already numbers in excess of 70 markets, Cambodia also ranks among the lowest on a global scale. The country’s ranking is unlikely to improve significantly in the short term, given the negative influence of a combination of factors including the existence of counterfeiting activities, the population’s low purchasing power and the lack of a national health insurance scheme.

Moreover, given that it is flanked by the more advanced economies and thus more developed pharmaceutical markets of Thailand and Malaysia, Cambodia has – to date – largely been sidelined by multinationals that have sought to take advantage of emerging opportunities in non-Western countries. Although Cambodia’s commitment to industrialisation and its receptiveness to foreign investment – alongside encouraging demographic factors – are sufficient to pique foreign interest in its pharmaceutical market, multinationals are likely to continue investing in less risky and more promising markets in the region.

In the absence of comprehensive official data for industrial production, healthcare expenditure and spending on medicines – among other statistics – in most emerging markets, we have devised a new system for deriving at more accurate estimates for the value of a country’s pharmaceutical market. We estimate that Cambodia’s pharmaceutical spending at consumer prices was worth around US$172mn in 2009, with this figure based on calculations taking into account pharmaceutical exports and imports, as well as the country’s wider economic performance. Through to 2014, we forecast that the market will grow at a compound annual growth rate (CAGR) of 12.09% in local currency terms, or 12.38% in US dollars, to reach the value of US$309mn.

While Cambodia experienced a full-year recession in 2009 - its first since records began in the late 1980s - over the longer term, we continue to believe that the country can return to 7% real GDP growth, basing this belief on its economy´s low base, favourable demographics, and natural resource wealth. However, such a scenario would be contingent on the authorities driving through substantial reform to boost infrastructure, improve governance and remain internationally competitive. Labour remains cheap and abundant, but less so than in Asian rivals Bangladesh and Myanmar. More worryingly, corruption, bureaucracy and poor infrastructure are all obstacles to long-term productivity and investment, which will also continue to have a negative effect on the development of the country’s healthcare and pharmaceutical markets.

Click for report details: www.companiesandmarkets.com/Summary-Market-Report/cambodia-pharm ..

Comments

Search RSS

All rights reserved."